Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Thursday, March 31, 2022.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2022 (2022-03-31): -18.19%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-105.46%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$2.06B
Return on Equity (ROE)
N/A
TTM Avg
-101.38%
3Y Avg
-17.29%
5Y Avg
175.33%
Market Cap
$2.05B
Return on Equity (ROE)
16.36%
TTM Avg
13.19%
3Y Avg
3.41%
5Y Avg
-4.94%
Market Cap
$2.11B
Return on Equity (ROE)
9.17%
TTM Avg
8.21%
3Y Avg
8.13%
5Y Avg
7.80%
Market Cap
$2.02B
Return on Equity (ROE)
-48.43%
TTM Avg
-97.59%
3Y Avg
-126.46%
5Y Avg
-100.04%
Market Cap
$2.02B
Return on Equity (ROE)
51.09%
TTM Avg
25.46%
3Y Avg
0.90%
5Y Avg
-9.89%
Market Cap
$2.01B
Return on Equity (ROE)
-16.25%
TTM Avg
-99.56%
3Y Avg
-48.75%
5Y Avg
-32.00%
Market Cap
$2.00B
Return on Equity (ROE)
-13.09%
TTM Avg
-10.89%
3Y Avg
-18.29%
5Y Avg
-19.41%
Market Cap
$1.97B
Return on Equity (ROE)
-8.14%
TTM Avg
-6.28%
3Y Avg
-6.47%
5Y Avg
-2.03%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alvotech (ALVO) | $2.07B | N/A | -105.46% | N/A | N/A |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.06B | N/A | -101.38% | -17.29% | 175.33% |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.05B | 16.36% | 13.19% | 3.41% | -4.94% |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 9.17% | 8.21% | 8.13% | 7.80% |
| Immunome, Inc. (IMNM)vs › | $2.02B | -48.43% | -97.59% | -126.46% | -100.04% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 51.09% | 25.46% | 0.90% | -9.89% |
| Fortrea Holdings Inc. (FTRE)vs › | $2.01B | -16.25% | -99.56% | -48.75% | -32.00% |
| AxoGen, Inc. (AXGN)vs › | $2.00B | -13.09% | -10.89% | -18.29% | -19.41% |
| Azenta, Inc. (AZTA)vs › | $1.97B | -8.14% | -6.28% | -6.47% | -2.03% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.17B | -42.07% | -35.11% | -34.40% | -30.49% |
ROE
N/A
ROA
-11.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2022-03-31 | -18.19% |
| 2021-09-30 | -159.26% |
| 2021-06-30 | -142.99% |
| 2021-03-31 | -101.42% |
| 2020-09-30 | -74.21% |
